Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 4/2013

01-12-2013 | Allergy and Immunology (SP Peters and JJ Oppenheimer, Section editors)

The small airways in asthma

Authors: Anita Trikha, Richard J. Martin

Published in: Current Pulmonology Reports | Issue 4/2013

Login to get access

Abstract

Airway inflammation is the basis for airway hyper-reactivity that results in the signs and symptoms of asthma. Great strides have been made in the past several decades to target airway inflammation using topical inhaled corticosteroids. In some cases, despite reported improvement in large airways indices on treatment, clinical control of asthma is not attained. Inflammation of the distal airways is now realized as playing a greater role in asthma control, and newer techniques are available to assess the smaller airways. Changes in formulations of inhaled corticosteroids and smaller particle size of medication allows for more effective targeting of the smaller airways.
Literature
1.
Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. New Engl J Med. 1968;278:1355–60.PubMedCrossRef
2.
Peters SP, Jones CA, Haselkorn T, et al. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol. 2007;119:1454–61.PubMedCrossRef
3.
4.
5.
Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170:836–44.PubMedCrossRef
6.
Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis. 1993;147:405–10.PubMedCrossRef
7.
Hetzel MR, Clark TJ. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax. 1980;35:732–8.PubMedCrossRef
8.
Hetzel MR, Clark TJ, Branthwaite MA. Asthma: analysis of sudden deaths and ventilatory arrests in hospital. Br Med J. 1977;1:808–11.PubMedCrossRef
9.
Kraft M, Martin RJ, Wilson S, et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med. 1999;159:228–34.PubMedCrossRef
10.
Haley KJ, Sunday ME, Wiggs BR, et al. Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med. 1998;158:565–72.PubMedCrossRef
11.
Lambert RK, Wiggs BR, Kuwano K, et al. Functional significance of increased airway smooth muscle in asthma and COPD. J Appl Physiol. 1993;74:2771–81.PubMedCrossRef
12.
Schulman ES, Adkinson Jr NF, Newball HH. Cyclooxygenase metabolites in human lung anaphylaxis: airway vs. parenchyma. J Appl Physiol. 1982;53:589–95.PubMed
13.
Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol. 2003;112:58–63.PubMedCrossRef
14.
Hyde DM, Hamid Q, Irvin CG. Anatomy, pathology, and physiology of the tracheobronchial tree: emphasis on the distal airways. J Allergy Clin Immunol. 2009;124:S72–7.PubMedCrossRef
15.
Irvin CG, Pak J, Martin RJ. Airway-parenchyma uncoupling in nocturnal asthma. Am J Respir Crit Care Med. 2000;161:50–6.PubMedCrossRef
16.
Kraft M, Pak J, Martin RJ, et al. Distal lung dysfunction at night in nocturnal asthma. Am J Respir Crit Care Med. 2001;163:1551–6.PubMedCrossRef
17.
Wagner EM, Liu MC, Weinmann GG, et al. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis. 1990;141:584–8.PubMedCrossRef
18.
Kraft M, Cairns CB, Ellison MC, et al. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest. 2006;130:1726–32.PubMedCrossRef
19.
Mahut B, Peiffer C, Bokov P, et al. Gas trapping is associated with severe exacerbation in asthmatic children. Respir Med. 2010;104:1230–3.PubMedCrossRef
20.
in’t Veen JC, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med. 2000;161:1902–6.CrossRef
21.
McFadden Jr ER, Kiser R, DeGroot WJ. Acute bronchial asthma. Relations between clinical and physiologic manifestations. New Engl J Med. 1973;288:221–5.PubMedCrossRef
22.
Zeidler MR, Goldin JG, Kleerup EC, et al. Small airways response to naturalistic cat allergen exposure in subjects with asthma. J Allergy Clin Immunol. 2006;118:1075–81.PubMedCrossRef
23.
Kaminsky DA, Irvin CG, Gurka DA, et al. Peripheral airways responsiveness to cool, dry air in normal and asthmatic individuals. Am J Respir Crit Care Med. 1995;152:1784–90.PubMedCrossRef
24.
Sutherland ER, Martin RJ, Bowler RP, et al. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol. 2004;113:1046–50.PubMedCrossRef
25.
• Shi Y, Aledia AS, Tatavoosian AV, et al. Relating small airways to asthma control by using impulse oscillometry in children. J Allergy Clin Immunol. 2012;129:671–8. Good demonstration of a new technique to assess small airways in a population traditionally difficult to assess with traditional office spirometry.PubMedCrossRef
26.
Bhansali PV, Irvin CG, Dempsey JA, et al. Human pulmonary resistance: effect of frequency and gas physical properties. J Appl Physiol. 1979;47:161–8.PubMed
27.
Lee JH, Lee YW, Shin YS, et al. Exercise-induced airway obstruction in young asthmatics measured by impulse oscillometry. J Investig Allergol Clin Immunol. 2010;20:575–81.PubMed
28.
• Liang BM, Lam DC, Feng YL. Clinical applications of lung function tests: a revisit. Respirology. 2012;17:611–9. Good review of available techniques available to assess the airways with description of limitations.PubMedCrossRef
29.
•• van der Wiel E, ten Hacken NH, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol. 2013;131:646–57. Excellent review of the literature relating to small airways and limitations in evaluating the distal lung.PubMedCrossRef
30.
Scichilone N, Battaglia S, Taormina S, et al. Alveolar nitric oxide and asthma control in mild untreated asthma. J Allergy Clin Immunol. 2013;131:1513–7.PubMedCrossRef
31.
Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J. 2005;25:986–91.PubMedCrossRef
32.
Okazawa M, Muller N, McNamara AE, et al. Human airway narrowing measured using high resolution computed tomography. Am J Respir Crit Care Med. 1996;154:1557–62.PubMedCrossRef
33.
Verbanck S, Schuermans D, Paiva M, Vincken W. Nonreversible conductive airway ventilation heterogeneity in mild asthma. J Appl Physiol. 2003;94:1380–6.PubMed
34.
Patel P, Mukai D, Wilson AF. Dose–response effects of two sizes of monodisperse isoproterenol in mild asthma. Am Rev Respir Dis. 1990;141:357–60.PubMedCrossRef
35.
Zanen P, Go LT, Lammers JW. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996;51:977–80.PubMedCrossRef
36.
Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497–504.PubMedCrossRef
37.
Sutherland ER, Martin RJ. Targeting the distal lung in asthma: do inhaled corticosteroids treat all areas of inflammation? Treat Respir Med. 2005;4:223–9.PubMedCrossRef
38.
Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol. 2009;124:S88–93.PubMedCrossRef
39.
Tamura G, Sakae H, Fujino S. In vitro evaluation of dry powder inhaler devices of corticosteroid preparations. Allergol Int. 2012;61:149–54.PubMedCrossRef
40.
Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7:1839–44.PubMedCrossRef
41.
Vanden Burgt JA, Busse WW, Martin RJ, et al. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol. 2000;106:1209–26.PubMedCrossRef
42.
Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346–53.PubMedCrossRef
43.
Corren J, Nelson H, Greos LS, et al. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients. Ann Allergy Asthma Immunol. 2001;87:405–11.PubMedCrossRef
44.
Gross G, Thompson PJ, Chervinsky P, Vanden BJ. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest. 1999;115:343–51.PubMedCrossRef
45.
Aubier M, Wettenger R, Gans SJ. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(−1)) versus HFA-fluticasone propionate (1000 microg day(−1)) in patients with asthma. Respir Med. 2001;95:212–20.PubMedCrossRef
46.
Fairfax AJ. The relative clinical effectiveness of HFA-BDP and fluticasone propionate in asthma. Respir Med. 2000;94(Suppl D):S31–6.PubMed
47.
•• Barnes N, Price D, Colice G, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy. 2011;41:1521–32. Initial evidence of effects on asthma control and treatment as it relates to smaller drug particle size.PubMedCrossRef
48.
Yamaguchi M, Niimi A, Ueda T, et al. Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Therapeut. 2009;22:326–32.CrossRef
49.
•• Price D, Martin RJ, Barnes N, et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol. 2010;126:511–8. e1-10. Evidence for the benefits of targeting the distal lung to acheive improvement in control.PubMedCrossRef
50.
Cohen J, Douma WR, ten Hacken NH, et al. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J. 2008;31:1213–20.PubMedCrossRef
51.
•• Corda L, Gardenghi GG, Modina D, et al. Effects on small airway obstruction of long-term treatments with beclomethasone/formoterol hydrofluoroalkane (metered-dose inhaler) versus fluticasone/salmeterol (dry-powder inhaler) in asthma: a preliminary study. Allergy Asthma Proc. 2011;32:29–34. Again, evidence supporting the utility of targeting the smaller airways.PubMedCrossRef
52.
• Vos W, De Backer J, Poli G, et al. Novel functional imaging of changes in small airways of patients treated with extrafine beclomethasone/formoterol. Respiration. 2013. Evidence for utility of emerging technological advances that could be clinically useful in years to come.
Metadata
Title
The small airways in asthma
Authors
Anita Trikha
Richard J. Martin
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 4/2013
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-013-0061-1

Other articles of this Issue 4/2013

Current Pulmonology Reports 4/2013 Go to the issue

Interstitial Lung Disease (G Tino, Section editor)

Lung cancer in idiopathic pulmonary fibrosis

Interstitial Lung Disease (G Tino, Section editor)

Combined pulmonary fibrosis and emphysema

Respiratory Infections (CL Daley, Section Editor)

Management of drug-resistant tuberculosis

Interstitial Lung Disease (G Tino, Section editor)

GERD and idiopathic pulmonary fibrosis: cause or effect

Interstitial Lung Disease (G Tino, Section editor)

Acute exacerbation of idiopathic pulmonary fibrosis: a proposal

Respiratory Infections (CL Daley, Section Editor)

Management of community-acquired pneumonia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits